Related Experiment Video
Updated: Nov 1, 2025

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
[ESKETAMINE FOR TREATMENT RESISTANT DEPRESSION: RESEARCH AND RISK MANAGEMENT]
Adi Marom1, Paola Rosca2,3
1The Hebrew University and Hadassah Medical School, Jerusalem, Israel.
Introduction:
About 15-18% of the population will experience depression in their lifetime. One third among them will suffer from treatment resistant depression (TRD) which does not respond to two accepted treatment protocols. There is a pressing need for effective TRD treatments and especially for a rapid-acting drug for patients with suicidal ideation. Nasal spray esketamine, the S-enantiomer of the anesthetic agent and dissociative drug ketamine, was approved by the FDA to treat TRD in 2019 and was included in the 2020 Israeli Healthcare Basket. Clinical research suggests that esketamine, combined with an oral antidepressant, has a sustainable antidepressant effect as well as a manageable safety profile. However, ketamine has abuse potential and may cause adverse effects that require medical attention. The risk management plan includes administration under direct medical supervision in ambulatory care, and monitoring of blood pressure, awareness changes, dissociation, and dependence symptoms.
Related Concept Videos
Electroconvulsive Therapy
Antidepressant Drugs: MAOIs and Other Agents
Psychosis: Goals of Pharmacotherapy
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Drug Therapy
Antianxiety Medications
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

